leadf
logo-loader
viewShield Therapeutics PLC

Shield Therapeutics remain optimistic about US commercialisation of Accrufer in the US

Shield Therapeutics PLC (LON:STX) Chief Executive Tim Watts joins Proactive London's Katie Pilbeam to discuss their financial and operational update.

Watts highlights the European sales volumes of its breakthrough iron deficiency drug Feraccru which grew by 70% year-on-year.

He concentrates on the discussions that are ongoing with potential US out-licensing partners for Accrufer in the States (Feraccru).

Quick facts: Shield Therapeutics PLC

Price: 39.6 GBX

LSE:STX
Market: LSE
Market Cap: £46.94 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Shield Therapeutics PLC named herein, including the promotion by the Company of Shield Therapeutics PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Shield Therapeutics raise £25m to launch Accrufer in US 'offering...

Shield Therapeutics PLC's (LON:STX) Tim Watts is 'delighted' by successful raise of £25mln through a share placing and subscription at 30p to launch and market its Accrufer iron deficiency treatment in the US. He also plans to offer an open opportunity to existing shareholders is also being...

1 week ago

2 min read